Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + SOX chemotherapy in first-line advanced gastric or gastroesophageal junction cancer
ChiCTR2600116087Phase 2Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Beijing Friendship Hospital. Primary endpoints: Objective Response Rate, 1-year Progression-Free Survival Rate and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on ChiCTR2600116087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116087.